Clinical trial · Observational
Endoscopic Characteristics of Duodenal and Ampullary Lesions
A Correlation of the Endoscopic Characteristics of Duodenal and Ampullary Laterally Spreading Tumours With Their Somatic or Germline Mutations.
NCT01556399CI-TRIAL-00087764DUO/AMP-LSTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose is to investigate whether polyps that look different at endoscopy, have formed via different mutations and have different risks of turning into cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Duodenal Diseases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tissue Sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Duodenal adenomas
- description
- Patients who consent to participate in this study will have a small sample of their adenoma and normal tissue sent for molecular testing.
- interventionNames
- Other: Tissue Sampling
Primary outcomes (1)
- measure
- Significant differences in molecular abnormalities.
- timeFrame
- Specimens will be stored and used for up to 15 years
- description
- The aim of this project is to look for statistically significant differences in molecular abnormalities from the three known genetic pathways, between the two different morphological types, granular and non-granular, to potentially demonstrate that these different polyps form via different genetic pathways.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Intention to perform Endoscopic Mucosal Resection * Adenoma equal to or greater than 20mm * over 18 years of age * Able to give informed consent to involvement in trial Exclusion Criteria: * Pregnancy * Lactation: currently breastfeeding * Taken clopidogrel within 7 days * Taken warfarin within 5 days * Had full therapeutic dose unfractionated heparin within 6 hours * Had full therapeutic dose low molecular weight heparin (LMWH) within 12 hours * Known clotting disorder
References
Publications (0)
Data not yet available
No reference posted for this study.